Pegcetacoplan Use in Adults and Adolescents with FSGS: Rationale and Design of a Sequential Phase 2/3 Study (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #INFO09-SA; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "A potential interim analysis (≥12 patients have completed ≥8 weeks) and the primary week-12 analysis will inform the conduct of phase 3. This study assessing the efficacy and safety of pegcetacoplan plus SOC in adults and adolescents with FSGS will inform future treatment options."
Clinical • P2/3 data • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • Renal Disease
|
|
Jonathan Barratt; Cristian Riella; Yiming Chen; Jinny Min; Joel Melnick
|